# The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.

> **NCT02283476** · PHASE3 · UNKNOWN · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Endostar continuous intravenous infusion
- **DRUG:** Endostar routine intravenous infusion
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT02283476
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2014-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283476, "The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02283476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*